Merck & Co Inc (Merck & Co Inc) received a 'buy' rating upgrade from Deutsche Bank, which anticipates a clear post-Keytruda patent strategy. Analyst James Shin raised the price target from $115 to $150, highlighting increasing diversification in oncology. Additionally, Barclays includes Merck among its preferred biopharma picks for 2026, despite competition from Bristol Myers. These positive views underscore the medium-term growth potential of the stock, drawing investor attention to its strategic positioning and outlook.

Merck & Co (NYSE: MRK) is facing an imminent patent cliff risk, similar to one recently avoided by AbbVie, which could impact its short-term revenues. However, the company is boosting its growth outlook through a multi-year strategic partnership with Guardant Health to accelerate the development and commercialization of oncology drugs. This collaboration, alongside strong market interest in cancer therapy pipelines, positions Merck for potential medium-term growth despite uncertainties surrounding patents.

Merck (MRK) has surged over 32% in the past three months, driven by strong recent market performance and a rise to $111.01 (+2.54%) in the latest sessions. However, this gain doesn’t alleviate investor concerns over the upcoming loss of patent exclusivity (LOE) for its flagship drug Keytruda and declining Gardasil sales. These issues continue to pressure earnings forecasts and sustain a sell rating on the stock despite short-term positive momentum.